大血管手术后围术期心肌梗死与高死亡率相关:基于密歇根州质量改进协作数据库的回顾性队列研究
年龄、糖尿病、充血性心力衰竭、瓣膜病、冠心病及术前P2Y12拮抗剂使用与POMI风险升高相关;开放腹主动脉瘤修复和周围血管旁路术风险最高。尽管出院时循证治疗依从性高(β受体阻滞剂82.7%、抗血小板治疗95.7%),POMI患者1年死亡率仍高达37.42%,显著高于无POMI者的5.05%。
要点
- 大血管手术后POMI发生率为1.6%,与1年死亡率显著升高相关(37.42% vs 5.05%)。
- 糖尿病、冠心病、心衰、瓣膜病及术前P2Y12拮抗剂使用与POMI风险升高独立相关。
- 开放腹主动脉瘤修复和周围血管旁路术的POMI风险最高,需加强围术期心脏风险管理。
核心结论
- 尽管出院时循证治疗依从性高,POMI后1年死亡负担仍很重,POMI患者1年死亡率为37.42%,显著高于无POMI者的5.05%(χ2=589.3,P<.001)。
主要发现
- 与POMI风险升高相关的因素包括年龄(OR 1.032,95%CI 1.019-1.045,P<.001)、糖尿病(OR 1.514,95%CI 1.201-1.907,P<.001)、充血性心力衰竭(OR 1.519,95%CI 1.163-1.983,P=.002)、瓣膜病(OR 1.447,95%CI 1.024-2.046,P=.04)、冠心病(OR 1.381,95%CI 1.058-1.803,P=.02)及术前P2Y12拮抗剂使用(OR 1.37,95%CI 1.08-1.725,P=.009)。
- 开放腹主动脉瘤修复(OR 4.53,95%CI 2.73-7.517,P<.001)和周围血管旁路术(OR 2.375,95%CI 1.818-3.102,P<.001)与最高的POMI风险相关。
- POMI患者出院时接受循证治疗的比例较高,包括β受体阻滞剂(296例,82.7%)和抗血小板治疗(336例,95.7%)。
临床怎么用
- 对合并糖尿病、冠心病、充血性心力衰竭和瓣膜病的患者,术前应给予额外评估与优化。
- 对发生POMI的患者需采取积极治疗策略以降低术后死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients undergoing vascular surgery are at high risk of postoperative myocardial infarction (POMI). Postoperative myocardial infarction is independently associated with significant risk of in-hospital mortality. OBJECTIVE: To examine the association of patient and procedural characteristics with the risk of POMI after vascular surgery and determine the association of evidence-based therapies with longer-term outcomes. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of prospectively collected data within a statewide quality improvement collaborative database between January 2012 and December 2017. Patient demographics, comorbid conditions, and perioperative medications were captured. Patients were grouped according to occurrence of POMI. Univariate analysis and logistic regression were used to identify factors associated with POMI. The collaborative collects data from private and academic hospitals in Michigan. Patients undergoing major vascular surgery, defined as endovascular aortic aneurysm repair, open abdominal aortic aneurysm, peripheral bypass, carotid endarterectomy, or carotid artery stenting were included. Analysis began December 2018. MAIN OUTCOMES AND MEASURES: The presence of a POMI and 1-year mortality. RESULTS: Of 26 231 patients identified, 16 989 (65.8%) were men and the overall mean (SD) age was 69.35 (9.89) years. A total of 410 individuals (1.6%) experienced a POMI. Factors associated with higher rates of POMI were age (odds ratio [OR], 1.032 [95% CI, 1.019-1.045]; P < .001), diabetes (OR, 1.514 [95% CI, 1.201-1.907]; P < .001), congestive heart failure (OR, 1.519 [95% CI, 1.163-1.983]; P = .002), valvular disease (OR, 1.447 [95% CI, 1.024-2.046]; P = .04), coronary artery disease (OR, 1.381 [95% CI, 1.058-1.803]; P = .02), and preoperative P2Y12 antagonist use (OR, 1.37 [95% CI, 1.08-1.725]; P = .009). Procedurally, open abdominal aortic aneurysm (OR, 4.53 [95% CI, 2.73-7.517]; P < .001) and peripheral bypass (OR, 2.375 [95% CI, 1.818-3.102]; P < .001) were associated with the highest risk of POMI. After POMI, patients were discharged and received evidence-based therapy with high fidelity, including β-blockade (296 [82.7%]) and antiplatelet therapy (336 [95.7%]). A high portion of patients with POMI were dead at 1 year compared with patients without POMI (113 [37.42%] vs 993 [5.05%]; χ2 = 589.3; P < .001). CONCLUSIONS AND RELEVANCE: Despite high rates of discharge with evidence-based therapies, the long-term burden of POMI is substantial, with a high mortality rate in the following year. Patients with diabetes mellitus, coronary artery disease, congestive heart failure, and valvular disease warrant additional consideration in the preoperative period. Further, aggressive strategies to treat patients who experience a POMI are needed to reduce the risk of postoperative mortality.
引用
- Beaulieu RJ, Sutzko DC, Albright J, et al. Association of High Mortality With Postoperative Myocardial Infarction After Major Vascular Surgery Despite Use of Evidence-Based Therapies. JAMA Surg. 2020. PMID: 31800003. doi:10.1001/jamasurg.2019.4908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。